- Home
- AIFU vs ACXP Comparison
AIFU vs ACXP Comparison
Compare AIFU & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIFU
- ACXP
- Stock Information
- Founded
- AIFU 1998
- ACXP 2017
- Country
- AIFU China
- ACXP United States
- Employees
- AIFU N/A
- ACXP N/A
- Industry
- AIFU
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- AIFU
- ACXP Health Care
- Exchange
- AIFU NYSE
- ACXP Nasdaq
- Market Cap
- AIFU 7.3M
- ACXP 8.4M
- IPO Year
- AIFU 2007
- ACXP 2021
- Fundamental
- Price
- AIFU $0.18
- ACXP $0.39
- Analyst Decision
- AIFU
- ACXP Strong Buy
- Analyst Count
- AIFU 0
- ACXP 2
- Target Price
- AIFU N/A
- ACXP $10.00
- AVG Volume (30 Days)
- AIFU 33.7M
- ACXP 147.1K
- Earning Date
- AIFU 05-27-2025
- ACXP 05-13-2025
- Dividend Yield
- AIFU N/A
- ACXP N/A
- EPS Growth
- AIFU 61.54
- ACXP N/A
- EPS
- AIFU 1.15
- ACXP N/A
- Revenue
- AIFU $247,815,758.00
- ACXP N/A
- Revenue This Year
- AIFU N/A
- ACXP N/A
- Revenue Next Year
- AIFU N/A
- ACXP N/A
- P/E Ratio
- AIFU $0.15
- ACXP N/A
- Revenue Growth
- AIFU N/A
- ACXP N/A
- 52 Week Low
- AIFU $0.11
- ACXP $0.30
- 52 Week High
- AIFU $3.64
- ACXP $3.33
- Technical
- Relative Strength Index (RSI)
- AIFU N/A
- ACXP 48.88
- Support Level
- AIFU N/A
- ACXP $0.36
- Resistance Level
- AIFU N/A
- ACXP $0.43
- Average True Range (ATR)
- AIFU 0.00
- ACXP 0.03
- MACD
- AIFU 0.00
- ACXP 0.00
- Stochastic Oscillator
- AIFU 0.00
- ACXP 46.08
About AIFU FANHUA INC SPON ADS EACH REPR 20 ORD SHS
AIFU Inc is an independent financial services provider in China. It offer end-to-end business solutions spanning compliance, technology, products, services, operations, capital flow, and professional training. It connects customers with insurance protection, retirement planning, health management, asset management, and family governance services.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.